Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Toludesvenlafaxine extended release - Luye Pharma

Next Previous
Drug Profile

Toludesvenlafaxine extended release - Luye Pharma

Alternative Names: 4-Methylbenzoate desvenlafaxine hydrochloride; Anshufaxine hydrochloride extended release - Luye pharma; Ansofaxine hydrochloride extended release - Luye Pharma; Desvenlafaxine prodrug; LPM-570065; LY-03005; Ruoxinlin; Toludesvenlafaxine hydrochloride extended release - Luye Pharma; Toludesvenlafaxine hydrochloride sustained-release - Luye Pharma

Latest Information Update: 22 Jan 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Luye Pharma Group
  • Class Antidepressants; Anxiolytics; Benzoates; Cyclohexanols; Small molecules
  • Mechanism of Action Adrenergic uptake inhibitors; Dopamine uptake inhibitors; Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Major depressive disorder
  • Preregistration Generalised anxiety disorder

Most Recent Events

  • 13 Jan 2026 Preregistration for Generalised anxiety disorder in China (PO)
  • 13 Jan 2026 NMPA accepts NDA for toludesvenlafaxine for Generalised anxiety disorder for review
  • 13 Jan 2026 Efficacy and adverse events data from a phase III trial in Generalised anxiety disorder released by Luye Pharma Group

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top